Clinical Trial Update: Safety and Efficacy of NAFT900 in Children With Tinea Capitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating NAFT900 for safety and efficacy in children with tinea capitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tinea Capitis

Drugs mentioned

• NAFT900

Snippet

Sponsor: Merz North America, Inc. | Conditions: Tinea Capitis | Phase 2 | Status: WITHDRAWN